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A B S T R A C T
Background. Renal function is known to affect glucose metabolism. The aim of this study was to assess glucose metabolism in end-stage renal disease (ESRD) patients and in matched controls with normal renal function and to delineate its underlying pathophysiology. Methods. ESRD patients without diabetes mellitus on the active kidney transplant waiting list of a large European university hospital were metabolically phenotyped by an oral glucose tolerance test (OGTT) and by calculating insulin sensitivity and secretion indices. Matched controls with normal renal function were derived from the TUEF (Tuebingen Family) study cohort, which includes healthy non-diabetic individuals with an increased risk of developing type 2 diabetes. Matches were made for (i) gender, age and body mass index (BMI) (cohort 1) and for (ii) gender, age, BMI, fasting plasma glucose (FPG) and 2-h glucose in OGTT (cohort 2).
Results. A total of 107 patients (90 on haemodialysis and 17 on peritoneal dialysis) and two cohorts, each comprising 107 matched controls, were investigated. ESRD patients had significantly lower FPG. Additional matching for OGTT glucose concentrations revealed significantly lower insulin sensitivity in ESRD patients than in controls. This finding was abrogated after adjustment for triglyceride levels. Insulin secretion, however, was significantly higher in ESRD patients. Insulin kinetics during OGTT as well as C-peptide levels demonstrate higher insulin secretion to be a compensation for lower insulin sensitivity and not to result from impaired insulin clearance. Conclusion. Our study is the first to provide metabolic phenotyping in patients with ESRD and to compare them with matched controls with normal renal function. Glucose metabolism differs substantially between cohorts, with insulin resistance and a compensatory increase in insulin secretion in ESRD patients. 
I N T R O D U C T I O N
Disturbances in glucose metabolism have a profound impact on renal function, diabetes mellitus being the leading cause of endstage renal disease (ESRD) [1] . However, a progressive decline in renal function and the associated sequelae of chronic kidney disease (CKD) also affect glucose metabolism. This association has been of long-standing interest.
Under physiological conditions, renal gluconeogenesis accounts for $20% of endogenous glucose production/release, but can increase to as much as 50-100% of hepatic gluconeogenesis in an anhepatic state [2] . Furthermore, the kidney is involved in the degradation of insulin, such that 25% of the insulin secreted daily is cleared by glomerular filtration and tubular degradation. CKD and associated changes, including anaemia, azotaemia, metabolic acidosis, vitamin D deficiency, bone-mineral disease and chronic inflammation, are discussed as causes of insulin resistance [3] . Changes in insulin secretion are poorly characterized.
Various aspects of the pathophysiological interaction of the kidney and glucose metabolism have been studied in the past using different methodologies and patient groups [4] [5] [6] [7] [8] . Many of these studies were hampered by small sample size, incomplete metabolic characterization in retrospective analyses or the underrepresentation of CKD stage 5 patients with ESRD.
We compare a fully metabolically phenotyped cohort of ESRD patients from our kidney waiting list with controls from a large cohort of subjects with normal renal function at an increased risk for type 2 diabetes [Tuebingan Family study (TUEF) cohort], fully phenotyped by the same techniques. Using different match strategies, we provide a comprehensive metabolic assessment with absolute values for parameters of glucose metabolism in a large cohort of ESRD patients and matched controls with normal renal function and describe key determinants of the underlying pathophysiology, thus providing further insight into glucose metabolism in ESRD.
M A T E R I A L S A N D M E T H O D S

Subjects and matching
Subjects were derived from two cohorts at the Tübingen University Hospital. The ESRD cohort consisted of patients on the active waiting list for kidney transplantation at the Tübingen University Hospital Collaborative Transplant Center. Patients were evaluated as part of their regular annual waiting list examination. A routine baseline laboratory profile, including metabolic parameters, was taken after an overnight fast followed by a standard 75-g oral glucose tolerance test (OGTT) in patients with no known diabetes mellitus. Appointments were made such that haemodialysis (HD) patients were seen on a non-HD day (short interval). For patients on peritoneal dialysis (PD), the dialysis regime was paused the day before at 10 p.m. in order not to alter glucose metabolism. Manifest diabetes mellitus was an exclusion criterion for the current analysis. Investigations were approved by the Institutional Ethics Committee of the Medical Faculty of Tübingen (631/2012BO2) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients prior to investigation [9] .
Control subjects with normal renal function were taken from the TUEF cohort. This cohort included non-diabetic individuals with an increased risk of developing type 2 diabetes (family history of type 2 diabetes, gestational diabetes, pre-diabetes). Subjects with normal or impaired glucose tolerance (IGT) could be enrolled. The study protocol included medical history, physical examination, routine baseline laboratory and extended OGTT.
Matching was performed with propensity score matching, using the nearest match method of the MatchIt package in R (R Project for Statistical Computing, Vienna, Austria). The pool out of which the matching was performed comprised 2885 nondiabetic subjects, for which complete cases were available for basic anthropometric variables and glucose during OGTT. ESRD patients were matched with TUEF subjects and two matched cohorts were generated: The first cohort was matched for gender, age and body mass index (BMI) (cohort 1), and a second cohort was matched for gender, age, BMI, fasting plasma glucose (FPG, Glc0) and 2-h glucose (Glc120) in OGTT (cohort 2) (Fig. 1 ).
Analytical measurements
Baseline laboratory tests in all cohorts included determination of haemoglobin A1c (HbA1c) and plasma lipid levels. OGTT was performed with blood sampling at time points 0, 30, 60, 90 and 120 min for determination of glucose, insulin and Cpeptide. Patients with known diabetes mellitus or previously unknown diabetes mellitus and FPG !126 mg/dL upon presentation were excluded from OGTT. Clinical chemical parameters [plasma glucose, wide-range C-reactive protein (CRP), magnesium, triglycerides and creatinine (enzymatic), as well as total, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol] were measured on the ADVIA 1800 clinical chemistry analyzer, and insulin, C-peptide and ferritin concentrations were determined on the ADVIA Centaur XPT chemiluminescent immunoassay system (both instruments from Siemens Healthineers, Eschborn, Germany). HbA1c was
measured by high-performance liquid chromatography (Tosoh G8 HPLC analyzer, Tokyo, Japan). The haemoglobin level was determined using a Sysmex XN-1000 haematology analyzer (Sysmex Europe, Norderstedt, Germany).
Calculations
According to the American Diabetes Association criteria, the definition of pre-diabetes was as follows: FPG of 5.6-6.9 mmol/L [impaired fasting glucose (IFG)], 2-h plasma glucose in OGTT of 7.8-11.1 mmol/L (IGT) or an HbA1c level of 5.7-6.4% [10] .
Glucose metabolism was further characterized using indices for the estimation of insulin sensitivity and insulin secretion. These indices are derived from plasma glucose, insulin and C-peptide concentrations, either in the basal state or dynamically during OGTT:
Areas under the curve (AUCs) -area under the insulin curve (AUC INS ), calculated using trapezoidal integration; -area under the C-peptide curve (AUC C-peptide ), calculated using trapezoidal integration
Insulin sensitivity indices (basal)
-quantitative insulin sensitivity check index (QUICKI) ¼ 1/ (logIns0 þ logGlc0) [12] Insulin sensitivity indices (OGTT) 
Insulin secretion indices (OGTT)
setting insulin secretion in relation to insulin sensitivity
Statistical analysis
Data are provided as median [interquartile range (IQR)] or unadjusted mean 6 SEM. Non-normally distributed parameters were log transformed to approximate for normal distribution prior to statistical analysis. Differences between cohorts were tested using analysis of variance (ANOVA). For the analysis of influencing factors, multivariate linear regression analysis was used. Results with two-sided P-values 0.05 were considered statistically significant. The JMP 11.0 (SAS Institute, Cary, NC, USA) statistical software package was used.
R E S U L T S
Patient characteristics
A total of 107 ESRD patients on the active kidney transplant waiting list and 107 matched controls from each cohort were investigated. ESRD patients consisted of 59 males and 48 Table 2 . With the exception of HOMA-b, there were no statistical differences between the different forms of renal replacement therapy.
Metabolic differences between ESRD and cohort 1
Absolute values of glucose, insulin and C-peptide levels, as well as calculated indices, are shown in Table 3 .
Patients with ESRD had significantly lower FPG than matched controls with normal renal function (4.8 versus 5.2 mmol/L, P <0.0001; Table 3 , Fig. 2 ). The 2-h plasma glucose concentration in OGTT did not differ between groups. HbA1c was significantly lower in ESRD patients than in patients with normal renal function (P ¼ 0.0001; Table 3 ).
Basal insulin levels were higher in ESRD patients. ESRD patients demonstrated significantly higher insulin secretion as calculated by HOMA-b (P < 0.0001) and impaired insulin sensitivity in HOMA-IR (P ¼ 0.007). Dynamic indices derived from OGTT showed lower insulin sensitivity in ESRD patients than in matched controls (P ¼ 0.046, Matsuda ISI) and demonstrated higher insulin secretion, as calculated by IGI, which did not reach statistical significance (P ¼ 0.07) ( Table 3 ).
Metabolic differences between ESRD and cohort 2
Additional matching for glucose concentrations at fasting and 120 min after glucose challenge was performed to achieve 'virtual clamping' of glucose concentrations and to enable delineation of the underlying pathophysiology of altered glucose metabolism. Absolute values of glucose, insulin and C-peptide levels, as well as calculated indices, are displayed in Table 4 .
As a result of the match design, no difference was observed between FPG (Glc0) and 2-h glucose concentrations (Glc120) ( Table 4 ) or in the AUC of glucose concentrations during OGTT. Of note, HbA1c was significantly lower in ESRD patients than in patients with normal renal function (P ¼ 0.0002).
Insulin sensitivity. Insulin sensitivity, calculated as Matsuda ISI, was significantly lower in ESRD patients than in subjects with normal renal function (P ¼ 0.009; Table 4 ). This also holds true for other indices of insulin sensitivity (Table 4) .
When seeking to identify factors associated with insulin sensitivity, triglyceride levels (P < 0.0001) and the triglyceride:HDL ratio (P < 0.0001) were strongly associated with insulin sensitivity in multivariate analysis. Plasma triglyceride levels were markedly higher in ESRD patients (P < 0.0001; Fig. 3) . Levels of haemoglobin, ferritin and magnesium were not associated with insulin sensitivity. Higher levels of CRP displayed a trend towards reduced insulin sensitivity, albeit not reaching statistical significance (P ¼ 0.06). Nevertheless, adjustment for CRP levels was performed for further analysis. Notably, the difference in insulin sensitivity between cohorts (ESRD versus cohort 2) was completely abrogated after adjustment for triglyceride levels (P ¼ 0.30, adjusted for triglycerides and CRP). LDL levels had no effect on insulin sensitivity (P > 0.05, adjusted for CRP).
Insulin secretion. Insulin secretion, as assessed by the IGI, was significantly higher in ESRD patients than in controls with normal renal function (P ¼ 0.003; Table 4 ). Basal insulin levels were significantly higher in ESRD patients (P < 0.0001); however, insulin levels during OGTT, insulin levels at 2 h and the insulin AUC did not differ between cohorts, and insulin levels decreased in a comparable manner during the course of OGTT (all P > 0.05; Table 5 , Fig. 4 ). Cpeptide levels, on the other hand, were significantly higher in ESRD patients than in controls with normal renal function, both in steady state and dynamically during OGTT (Fig. 4) . The disposition index did not differ between ESRD patients and matched controls with normal renal function, suggesting that the increased IGI in ESRD patients was due to a compensatory hypersecretion to overwhelm insulin resistance (Table 4) .
D I S C U S S I O N
The present analysis reveals three major findings: CKD stage 5 patients with ESRD have lower FPG, reduced insulin sensitivity and compensatory higher insulin secretion than matched subjects with normal renal function.
Two pathomechanisms contribute to lower FPG in CKD stage 5 patients. First, particularly in the fasting state, the contribution of the kidney to gluconeogenesis and glucose release is significant [17] , resulting in lower glucose levels in ESRD. Second, ESRD patients display significantly higher fasting insulin levels. This hyperinsulinaemia reflects basal insulin 
In accordance with lower FPG, ESRD patients had lower HbA1c. Interestingly, this finding persisted, even in comparison with cohort 2, which had been additionally matched for glucose concentrations in OGTT. ESRD patients thus displayed lower HbA1c values while having the same glucose levels as subjects with normal kidney function. This corroborates previous studies that questioned the diagnostic value of HbA1c in patients with CKD [18] where anaemia, chronic azotaemia and higher erythrocyte turnover lead to lower HbA1c values [19] . Therefore, low HbA1c does not exclude diabetes in CKD stage 5 patients.
To investigate the underlying pathophysiology of altered glucose metabolism in ESRD, additional matching for glucose concentrations in OGTT was performed, thereby achieving 'virtual clamping' of glucose levels. In this setting, insulin sensitivity was markedly impaired in ESRD patients in comparison to controls with normal renal function. This is a known finding, as has basically been shown in early clamp studies in dialysis patients [4] . It has since been confirmed in several other studies, mostly using indices of fasting insulin sensitivity [20] [21] [22] on the basis of fasting glucose and insulin levels. However, these indices have proven less accurate in CKD patients than dynamic testing with estimates derived from OGTT [23] . The most recent epidemiological and cohort trials [7, 8] using dynamic estimates are cohorts classified by renal function only and mostly including patients with mild to moderate renal functional impairment. Our approach, with individual matching for anthropometrics and OGTT glucose concentrations, provides the most homogeneous comparison available, with ESRD as the principal influencing variable.
Factors proposed to affect insulin sensitivity in CKD patients include anaemia, azotaemia, acidosis and bone-mineral disease [3] . Additionally, we now recognize triglyceride levels as a principal factor associated with insulin sensitivity in CKD. Hypertriglyceridaemia is the most common disturbance in lipid metabolism in CKD [24, 25] . CKD alters both plasma lipid profile and lipid metabolism [26] . The interaction of triglyceride levels and insulin resistance is bidirectional. Hypertriglyceridaemia and increased free fatty acids contribute to insulin resistance [27, 28] , whereas insulin resistance in itself promotes hypertriglyceridaemia [29] . The relative contribution and predominant direction in patients with CKD is not known.
In multivariate analysis, the association of ESRD with insulin sensitivity in CKD stage 5 patients was completely abrogated after adjustment for triglyceride levels. This association supports the hypothesis that triglyceride levels contribute to insulin resistance in CKD, albeit causality cannot be proven from the present analysis. Since insulin resistance is known to be associated with increased cardiovascular risk [30, 31] , hypertriglyceridaemia, despite being part of reverse epidemiology [32] , may be a determinant of cardiovascular risk in ESRD patients via insulin resistance.
With regard to insulin secretion, IGI was higher in ESRD patients than in controls with normal renal function. One might speculate that higher insulin levels are due to decreased clearance of insulin caused by the loss of kidney function. Previous studies have shown, to some extent, decreased insulin clearance in CKD [33, 34] . In the present analysis however, despite higher fasting insulin levels in ESRD patients, postchallenge insulin dynamics and the AUC during OGTT did not differ between ESRD and cohort 2. This argues against a relevant difference in insulin clearance. C-peptide levels, on the other hand, showed a different course over time in ESRD patients: baseline values were almost five times higher, and levels continued to rise during OGTT, despite decreasing insulin levels (cf. Fig. 4 ). This is due to the principal role of the kidney in removing C-peptide from the circulation [35] . C-peptide-based indices for insulin secretion are therefore not valid in CKD.
Endogenous insulin is primarily degraded by the liver via the first-pass effect, whereas the kidney removes part of the remaining insulin from the circulation [36] . When exogenous insulin is used to treat diabetes mellitus, the relative contribution of the kidney in insulin metabolism is greater due to the missing firstpass effect. This could explain more frequent hypoglycaemia in CKD patients with insulin treatment [36] . In non-diabetic CKD patients, the overall effect of kidney function on insulin clearance is presumably small.
Taken together, physiological considerations and our data suggest that even though there might be a decrease in insulin clearance in CKD, higher insulin levels and estimates of insulin secretion in our ESRD patients are mainly a response to impaired insulin sensitivity in order to maintain normal glucose regulation.
One potential limitation of our investigations is a bias from patient selection. First, waiting list patients present a positive selection among dialysis patients, albeit the present cohort did have a substantial dialysis vintage [median 4.3 (IQR 2.8-6.5) years]. Second, the control group, consisting of patients with a potential risk for type 2 diabetes, may be slightly less healthy than the general population. As a consequence, in the matching process, we cannot fully exclude that we created a control group with impaired insulin secretion, making the b-cell response relative to insulin sensitivity appear higher in ESRD patients. However, we did our utmost to exclude subtle differences in glucose tolerance status by additionally matching for fasting and postprandial glucose in cohort 2.
Of note, when interpreting our data it is important to bear in mind that HOMA indices reflect only basal insulin resistance or insulin secretion. Even in subjects with normal renal function, these are less precise than dynamic indices obtained from OGTT. In CKD patients, this is aggravated by the fact that HOMA is strongly determined by insulin clearance [37] , which is reduced in CKD. In our analysis, dynamic indices rendered results that were similar to those of the HOMA indices. Despite having dynamic indices, we have included HOMA indices for comparative reasons, since most publications provide only the latter.
In conclusion, we provide a comprehensive metabolic assessment of ESRD patients and matched controls with normal renal function. Our findings provide further insight into insulin dynamics and the role of hypertriglyceridaemia in insulin resistance in ESRD, thereby proposing a novel target to reduce cardiovascular risk in CKD. 
